An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants

被引:0
作者
Dean F. Wong
Arash Raoufinia
Patricia Bricmont
James R. Brašić
Robert D. McQuade
Robert A. Forbes
Tetsuro Kikuchi
Hiroto Kuwabara
机构
[1] Mallinckrodt Institute of Radiology,Lab of CNS Neuropsychopharmacology And Multimodal Imaging (CNAMI)
[2] Washington University in St. Louis,Section of High Resolution Brain PET, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science
[3] Otsuka Pharmaceutical Development & Commercialization Inc,undefined
[4] Johns Hopkins University School of Medicine,undefined
[5] Otsuka Pharmaceutical Co.,undefined
[6] Ltd,undefined
来源
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词
Antipsychotic agents; Brexpiprazole; Dopamine receptors; Dose determination; Positron-emission tomography; Raclopride; Receptor occupancy; Target engagement;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:717 / 725
页数:8
相关论文
共 208 条
[1]  
Maeda K(2014)Brexpiprazole I: J Pharmacol Exp Ther 350 589-604
[2]  
Sugino H(2015) and Am J Psychiatry 172 870-880
[3]  
Akazawa H(2015) characterization of a novel serotonin–dopamine activity modulator Schizophr Res 164 127-135
[4]  
Amada N(2017)Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial Int J Neuropsychopharmacol 20 11-21
[5]  
Shimada J(2015)A multicenter, randomized, double-blind, controlled Phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia J Clin Psychiatry 76 1224-1231
[6]  
Futamura T(2015)Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 76 1232-1240
[7]  
Yamashita H(2018)Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants Curr Med Res Opin 34 633-642
[8]  
Ito N(1988)Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study Arch Gen Psychiatry 45 71-76
[9]  
McQuade RD(1993)Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study Biol Psychiatry 33 227-235
[10]  
Mørk A(2000)Central D Am J Psychiatry 157 514-520